Kendle Names Louis A. Angelucci III Vice President, Validation
Angelucci Brings Global Experience in Validation, cGMP to Leadership Role in Regulatory Affairs Division
CINCINNATI, April 12, 2005 -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of Louis A. Angelucci III as Vice President, Validation, for its AAC Consulting Group, Inc., subsidiary based in Rockville, Md. Angelucci will oversee the day-to-day operations of the validation unit and maintain the quality and consistency of its service to clients.
Angelucci most recently served as Senior Director of Validation and Compliance in the life sciences division of global engineering and construction firm Technip. His prior experience includes serving as Vice President of Validation Operations for a major pharmaceutical firm, and responsibility for the global validation activities for two international companies.
"Lou brings more than 20 years experience in all aspects of cGMP, validation and validation project management to Kendle," says Edward A. Steele, Vice President of U.S. Regulatory Consulting and Submissions. "He also has experience working on commissioning, validation and cGMP issues with clients around the globe, and is familiar with U.S. and European regulations."
Angelucci earned Master of Science degrees in Engineering Management from Drexel University in 1990, and in Biomedical Engineering from the University of Pennsylvania in 1980. He earned a Bachelor of Science in biology from Ursinus College in 1977.
Angelucci is a member of the International Society of Professional Engineers (IPSE) and the board of directors of the Institute of Validation Technology (IVT). He serves as adjunct professor at both Temple University and the Stevens Institute of Technology. He also is a member of the industry advisory board for the Stevens Institute.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions--from first-in-human studies through market launch and surveillance--to help the world's biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our more than 1,700 associates worldwide, Kendle has conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. Investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street,Cincinnati, OH 45202, or from the company's Web site at www.kendle.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
